title: [Reaferon in the treatment of hemorrhagic fever with the renal syndrome].
abstract: Ninety six patients with hemorrhagic fever and the renal syndrome were followed up. Reaferon was included into the complex therapy of 57 cases. The drug was administered intramuscularly in a dose of 2 x 10(6) IU twice a day for 5 days. The use of reaferon in the complex therapy resulted in a decrease in the period of the general intoxication by 3.4 +/- 1.3 days. The use of the drug at the initial stages prevented acute renal failure. When reaferon was used at the stage of oliguria, the level of proteinuria and the risk of the further affection of the kidneys lowered. After the completion of the treatment course with the use of reaferon, a significant increase in the content of the T-helper cells was observed which could be indicative of an activation of the mechanisms providing the immunity development and pathogen elimination. Reaferon promoted a decrease in the concentration of the circulating immune complexes of the blood serum. No significant adverse reactions to the use of reaferon were recorded. The results are in favour of the reaferon use in complex therapy of patients with hemorrhagic fever and the renal syndrome, especially at the initial stages until the syndrome of acute renal failure developed.
authors.forename: K S
authors.initials: KS
authors.lastname: Ivanov
authors.forename: V I
authors.initials: VI
authors.lastname: Roshchupkin
authors.forename: O I
authors.initials: OI
authors.lastname: Koshil'
authors.forename: V G
authors.initials: VG
authors.lastname: Morozov
authors.forename: V N
authors.initials: VN
authors.lastname: Utkin
mesh_terms: D000293:Adolescent; D000328:Adult; D000936:Antigen-Antibody Complex / Q000097:blood; D003131:Combined Modality Therapy; D006482:Hemorrhagic Fevers, Viral / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D007674:Kidney Diseases / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D011994:Recombinant Proteins; D012307:Risk Factors; D013577:Syndrome
chemical_list: D000936:Antigen-Antibody Complex; D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins
vernacular_title: Primenenie reaferona dlia lecheniia gemorragicheskoĭ likhoradki s pochechnym sindromom.